


QuantideX[®]

NGS Pan Cancer Kit



TARGETED SEQUENCING, SIMPLIFIED.

The QuantideX[®] NGS Pan Cancer Kit* is a next-generation sequencing (NGS) based workflow that incorporates both a multiplexed, gene specific PCR panel as well as supporting workflow elements, including the analytical and reporting features within one comprehensive kit.

The kit, interrogates 46 gene regions (amplicons) within 21 genes, with high clinical* significance in various human cancers. The scope of variants reported by the panel include >1,600 known COSMIC variants, including single nucleotide variants (SNVs) and insertions-deletions (indels) targeted by the panel. The kit includes all reagents for pre-analytical DNA QC/quantification, gene specific PCR, library purification and quantification for sequencing with Illumina chemistry.



QUANTIDEX[®] NGS REPORTER

The modular kit design, also incorporates an easy-to-use push-button analysis and reporting tool, the QuantideX[®] NGS Reporter, tailored to labs wishing to adopt an NGS-based test with minimal startup costs and regardless of NGS experience.



THE MOST RELEVANT PAN-CANCER* CONTENT

Multiplexed profiling of the most clinically actionable mutations in a wide range of human cancers with high performance in low quality/quantity samples

STREAMLINED & EFFICIENT

Designed and optimized for rapid deployment, regardless of NGS experience or knowledge-level

A COMPREHENSIVE NGS WORKFLOW

A comprehensive workflow, containing all elements for ready-to-go Illumina sequencing, including sample QC, library prep, clean up and quantification

ANALYTICS & REPORTING

Leverages Asuragen's integrated analytics and reporting suite, The QuantideX[®] NGS Reporter, providing a straight forward sample-to-answer solution for Asuragen NGS panels

ACTIONABLE, CLINICALLY-RELEVANT GENE CONTENT

	Lung	Melanoma	Colorectal	Breast/Ovarian	Thyroid	Leukemia/ Lymphomas	Pancreatic, Gastric, Sarcomas, Glioblastomas & Other
In Clinical Guidelines	EGFR	BRAF KIT	KRAS BRAF NRAS		BRAF RET	ABL1	
Emerging Therapeutic Targets	AKT1 BRAF RET MET ERBB2	FGFR1 NRAS KRAS ALK1	PIK3CA NRAS AKT1 AKT2 EGFR PIK3CA MET	AKT1 AKT2 PIK3CA ERBB2	KRAS NRAS	FGFR3 FLT3 JAK2	AKT1 ALK1 BRAF EGFR FGFR3 HRAS IDH1 IDH2 KRAS MET NRAS PDGFRA PIK3CA RET



*Research Use Only. Not for use in diagnostic procedures.



QuantideX[®]

NGS Pan Cancer Kit



KIT ORDERING INFORMATION

QUANTIDEX[®] NGS PAN CANCER KIT*
[P/N 49560] 48 Reactions, Full NGS Workflow

QUANTIDEX[®] qPCR DNA QC ASSAY*
[P/N 49539] 100 Reactions.

QUANTIDEX[®] NGS PAN CANCER KIT* Core Reagents
[P/N 49559] 48 Reactions

*Research Use Only. Not for use in diagnostic procedures.

QUANTIDEX[®] NGS CODES (SET A, B, C & D)
[P/N 49553, 49554, 49555, 49556] 192 Reactions

QUANTIDEX[®] NGS PAN CANCER KIT* Bundle Pack
[P/N 49561] 192 Reactions, Full NGS Workflow

QUANTIDEX[®] NGS REPORTER
[P/N 49539]

REFERENCES

1. Functional DNA quantification guides accurate next-generation sequencing mutation detection in formalin-fixed, paraffin-embedded tumor biopsies. Sah et al. *Genome Med* 2013;5(8):77
2. Evaluation of an integrated clinical workflow for targeted next-generation sequencing of low-quality tumor DNA using a 51-gene enrichment panel. Choudhary et al. *BMC Med Genomics* 2014;(7):62

WATCH THE TECH TALK

“QuantideX[®] NGS: An integrated approach that links DNA and RNA inputs, informatics and workflows to create targeted NGS systems”

Presented by: Gary Latham, Ph. D.
www.asuragen.com/tech-talks

2500-0537

Overcoming Barriers with an Integrated NGS Solution

- Full integration across the complex parts of a full NGS workflow is needed to ensure reliable results
- An integrated analytics solution is needed to lower the barrier-to-entry for labs starting NGS
- Modular design allowing for content updates with minimal impact on established workflow

QuantideX Pan Cancer Kit
A Fully-Integrated NGS Solution



www.rafer.es

Barcelona

93 645 50 28
barcelona@rafer.es

Bilbao

94 499 85 80
bilbao@rafer.es

La Coruña

981 93 89 26
galicia@rafer.es

Madrid

91 365 15 70
madrid@rafer.es

Málaga

639 359 792
malaga@rafer.es

Sevilla

954 369 334
sevilla@rafer.es

Valencia

96 340 48 00
levante@rafer.es

Zaragoza

976 23 74 00
rafer@rafer.es

Lisboa

21 154 19 98
lisboa@rafer.es